secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001193125-25-210050
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA agrees MCH/H findings not dose-limiting for Rein Therapeutics' LTI-03 Phase 2 trial; CRL submission planned
--------------------------------------------------------------------------------

- FDA confirmed MCH/H findings in GLP rat studies are not dose-limiting for proposed 24-week LTI-03 protocol at doses up to 10 mg/day in IPF patients.
- FDA stated Complete Response Letter (CRL) need not include new GLP rat toxicity study; Rein will prepare CRL in coming weeks.
- FDA recommended CRL include updated clinical safety, PK/PD data, augmented safety monitoring with spirometry, and DSMB unblinded reviews.
- Clinical hold on U.S. Phase 2 RENEW trial (LTI-03) remains; company hopeful for timely release after CRL submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525210050/0001193125-25-210050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525210050/d902312d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-210050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer